Compare LINC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | DRUG |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 856.4M |
| IPO Year | 2005 | 2020 |
| Metric | LINC | DRUG |
|---|---|---|
| Price | $36.27 | $81.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $37.50 | ★ $114.00 |
| AVG Volume (30 Days) | ★ 472.4K | 90.3K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $261,853,000.00 | N/A |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | $150.39 | ★ N/A |
| Revenue Growth | ★ 32.98 | N/A |
| 52 Week Low | $14.10 | $23.18 |
| 52 Week High | $36.42 | $123.75 |
| Indicator | LINC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 77.68 | 50.24 |
| Support Level | $21.46 | $73.97 |
| Resistance Level | N/A | $97.75 |
| Average True Range (ATR) | 1.86 | 5.76 |
| MACD | 0.72 | 0.72 |
| Stochastic Oscillator | 98.17 | 53.97 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.